Extensive Breast Cancer Study Program

TKa patterns provide clinical utility by predicting and monitoring the efficacy of ET with or without CDK4/6 inhibitors.

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. [EJC, June 2023]

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). [Biomarkers, January 2023]

Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial. [Journal of Clinical Oncology, June 2022]

A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. [NPJ Breast Cancer, March 2022.]

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. [European Journal of Cancer, March 2022]

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

CLL, lymphoma, multiple myeloma

NSCLC, SCLC, benign lung disease

Pancreatic cancer, RCC, melanoma, solid tumors (general)